Results 81 to 90 of about 207,533 (298)

Targeted Anti‐IL‐1 Immunomodulatory Therapy in Pediatric Onset PPP1R13L‐Related Arrhythmogenic Cardiomyopathy

open access: yesAmerican Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Autosomal recessive loss‐of‐function variants in PPP1R13L cause an ultra‐rare cardiocutaneous syndrome characterized by rapidly progressive arrhythmogenic cardiomyopathy (ACM). PPP1R13L encodes iASPP, which has two potentially overlapping mechanisms driving ACM as both a regulator of NFκB‐mediated inflammation and a binding partner within the ...
Aaron Renberg   +9 more
wiley   +1 more source

Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). [PDF]

open access: yes, 2005
BACKGROUND: Treatment of late-stage human African trypanosomiasis (HAT) with melarsoprol can be improved by shortening the regimen. A previous trial demonstrated the safety and efficacy of a 10-day treatment schedule.
Asumu, P   +10 more
core   +2 more sources

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm   +2 more
wiley   +1 more source

Skin microbiota: a source of disease or defence?

open access: yes, 2008
Microbes found on the skin are usually regarded as pathogens, potential pathogens or innocuous symbiotic organisms. Advances in microbiology and immunology are revising our understanding of the molecular mechanisms of microbial virulence and the specific
Cogen, AL, Gallo, RL, Nizet, V
core   +1 more source

Interleukin‐5, Eosinophils, and Interleukin‐5 Pathway Inhibitors in Eosinophilic Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, EarlyView.
Interlukin‐5 (IL‐5) plays a crucial role in the pathogenesis of eosinophilic granulomatosis with polyangiitis (EGPA) by promoting eosinophil differentiation, activation, and survival. We present here a typical case of EGPA in which treatment with IL‐5 pathway inhibitors is prescribed, showing to be beneficial for the patient.
Alvise Berti, Christian Pagnoux
wiley   +1 more source

Intracerebral haemorrhage in a dog with steroid-responsive meningitis arteritis [PDF]

open access: yes, 2017
A one-year and six-month-old female neutered Boxer dog was presented with a four-day history of pyrexia, lethargy and neck pain. An intracerebral haemorrhage and a mediastinal mass were identified.
Brocal, Josep   +3 more
core   +1 more source

Interleukin‐18 Levels Are Associated With Disease Course in Patients With Still Disease Treated With Interleukin‐1 Inhibitors

open access: yesArthritis &Rheumatology, EarlyView.
Objective To evaluate the prognostic utility of circulating interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in patients with Still disease (SD) receiving first‐line IL‐1 inhibitors (IL‐1i).
Matteo Trevisan   +8 more
wiley   +1 more source

A Case Report: Cluster Headache in Childhood

open access: yesMedicine Science, 2014
Cluster headache (CH) is one of the most severe types of headache, characterized by periods of recurrent attacks of sudden and intense pain, localized in the orbital or temporal region, and associated with ipsilateral autonomic symptoms and signs.
Faik Ilik, Huseyin Caksen
doaj   +1 more source

Prescribing of Medication to Prevent Glucocorticoid Harms in Patients With Polymyalgia Rheumatica: A Cross‐Sectional Study and Two Emulated Target Trials in the Clinical Practice Research Datalink Aurum

open access: yesArthritis &Rheumatology, EarlyView.
Objective Polymyalgia rheumatica (PMR) is a common indication for long‐term glucocorticoid (GC) treatment. Bone‐protective and gastroprotective medications are recommended for those at high risk of adverse events from GCs, but no trials have evaluated their effectiveness in PMR.
Helen Twohig   +5 more
wiley   +1 more source

Combined atypical primary hypoadrenocorticism and primary hypothyroidism in a dog [PDF]

open access: yes, 2016
A dog with combined atypical primary hypoadrenocorticism and primary hypothyroidism is described. The dog presented with waxing and waning, vague complaints since more than a year and had been treated with several drugs without complete resolution of ...
Binst, Dominique   +5 more
core  

Home - About - Disclaimer - Privacy